Veru Inc (NASDAQ:VERU) Director Harry Fisch acquired 10,000 shares of the firm’s stock in a transaction on Monday, March 12th. The stock was purchased at an average cost of $1.80 per share, with a total value of $18,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Harry Fisch also recently made the following trade(s):
- On Friday, March 9th, Harry Fisch acquired 10,000 shares of Veru stock. The stock was purchased at an average cost of $1.88 per share, with a total value of $18,800.00.
- On Wednesday, March 7th, Harry Fisch acquired 24,000 shares of Veru stock. The stock was purchased at an average cost of $1.62 per share, with a total value of $38,880.00.
Veru Inc (VERU) traded down $0.06 during trading hours on Monday, reaching $1.76. 178,202 shares of the company’s stock were exchanged, compared to its average volume of 108,396. Veru Inc has a one year low of $0.90 and a one year high of $3.00. The stock has a market cap of $97.39, a PE ratio of -6.52 and a beta of 0.96.
VERU has been the subject of a number of analyst reports. ValuEngine cut shares of Veru from a “hold” rating to a “sell” rating in a research report on Friday, November 17th. HC Wainwright set a $5.00 price objective on shares of Veru and gave the company a “buy” rating in a research report on Tuesday, November 14th. Finally, Zacks Investment Research cut shares of Veru from a “hold” rating to a “strong sell” rating in a research report on Saturday, January 6th.
Veru Company Profile
Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.